SPG-601

Spinogenix's SPG601 demonstrated a significant reduction in high-frequency gamma band activity, an EEG abnormality associated with Fragile X syndrome (FXS).

The FDA granted breakthrough therapy designation to STK-001 for Dravet syndrome, highlighting its potential to improve upon current treatments by restoring NaV1.1 protein levels.

Spinogenix is developing SPG302 and SPG601, orally administered small molecules, to restore synapses in neurological diseases like ALS, Alzheimer's, schizophrenia, and Fragile X syndrome.

Spinogenix, Inc. has received Orphan Drug Designation from the FDA for its drug candidate SPG601, aimed at treating Fragile X Syndrome (FXS), a condition with no current FDA-approved therapies. SPG601 targets synaptic dysfunctions by modulating BK channels, offering hope for improving the quality of life for those affected by FXS.

Spinogenix, Inc. has been granted Orphan Drug Designation by the U.S. FDA for SPG601, a novel treatment for Fragile X syndrome (FXS), highlighting the urgent need for new therapies. FXS, a leading cause of inherited intellectual disability and autism, lacks FDA-approved treatments. SPG601 aims to address core symptoms by modulating BK channels to restore synaptic function.